Donanemab in Early Symptomatic Alzheimer Disease
Importance There are limited efficacious treatments for Alzheimer disease. Objective To assess efficacy and adverse events of donanemab, an antibody designed to clear brain amyl...
Publications
2 shownDonanemab in Early Alzheimer’s Disease
In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo a...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 3,386
- Institution
- Eli Lilly (United States)
External Links
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.